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Purpose: Adjuvant accelerated partial breast irradiation (APBI) results in low local
recurrence risks. However, the survival benefit of adjuvant radiotherapy APBI for low-risk
breast cancer might partially be offset by the risk of radiation-induced lung cancer.
Reducing the lung dose mitigates this risk, but this could result in higher doses to
the ipsilateral breast. Different external beam APBI techniques are equally conformal
and homogenous, but the intermediate to low dose distribution differs. Thus, the risk
of toxicity is different. The purpose of this study is to quantify the trade-off between
secondary lung cancer risk and breast dose in treatment planning and to compare an
optimal coplanar and non-coplanar technique.
Methods: A total of 440 APBI treatment plans were generated using automated
treatment planning for a coplanar VMAT beam-setup and a non-coplanar robotic
stereotactic radiotherapy beam-setup. This enabled an unbiased comparison of two
times 11 Pareto-optimal plans for 20 patients, gradually shifting priority from maximum
lung sparing to maximum ipsilateral breast sparing. The excess absolute risks of
developing lung cancer and breast fibrosis were calculated using the Schneider model
for lung cancer and the Avanzo model for breast fibrosis.
Results: Prioritizing lung sparing reduced the mean lung dose from 2.2Gy to as low
as 0.3Gy for the non-coplanar technique and from 1.9Gy to 0.4Gy for the coplanar
technique, corresponding to a 7- and 4-fold median reduction of secondary lung cancer
risk, respectively, compared to prioritizing breast sparing. The increase in breast dose
resulted in a negligible 0.4% increase in fibrosis risk. The use of non-coplanar beams
resulted in lower secondary cancer and fibrosis risks (p < 0.001). Lung sparing also
reduced the mean heart dose for both techniques.
Conclusions: The risk of secondary lung cancer of external beam APBI can
be dramatically reduced by prioritizing lung sparing during treatment planning. The
associated increase in breast dose did not lead to a relevant increase in fibrosis risk. The
use of non-coplanar beams systematically resulted in the lowest risks of secondary lung
cancer and fibrosis. Prioritizing lung sparing during treatment planning could increase
the overall survival of early-stage breast cancer patients by reducing mortality due to
secondary lung cancer and cardiovascular toxicity.
Keywords: breast cancer, radiotherapy techniques, accelerated partial breast irradiation, plan optimization,
secondary lung cancer
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INTRODUCTION
The prognosis of early-stage breast cancer patients is excellent,
with a cancer-specific survival of almost 99% at 5 years
(1). However, the mortality from radiation induced secondary
cancers, especially lung cancers, may offset the survival benefit
for certain subgroups (2, 3). There are several models that
quantitatively relate dose to the lungs to the risk of secondary
lung cancer (4, 5). Thus, reducing the amount of radiation to
the lungs during treatment planning could reduce the long-term
overall mortality of early stage breast cancer patients.
One option is the use of accelerated partial breast irradiation
(APBI) instead of whole breast irradiation (WBI) for early
stage breast cancer patients that are eligible according to
international guidelines (6–11). Long-term results of randomized
trials indicate that local control and survival are non-inferior
to whole breast radiotherapy (12–17). Dose comparison studies
have shown that the dose to the lungs is significantly lower
with APBI compared to WBI but varies greatly depending on
the APBI technique used (3, 18–23). The conformality and
homogeneity of the different contemporary APBI techniques
were similar (21–23). This means that the differences between the
external beam APBI techniques are not in the high dose region
but in the intermediate and low dose regions where radiation
induced malignancies occur. The protocols used in these studies
accepted a high lung dose constraint without recommendation to
minimize the lung dose well below this constraint. It is unknown
to what extent the lung dose can be reduced if highly prioritized
during treatment planning and how this impacts the dose to
other organs. In the case of APBI, reducing the dose to the lungs
mainly results in a higher dose to the ipsilateral non-target breast
tissue. For example, this might result in more breast toxicity
including fibrosis.
The aim of this study was 2-fold: First, we explored the trade-
off between reduction of the mean lung dose as a surrogate of
secondary cancer risk and the ipsilateral breast dose distribution
as a surrogate of the breast fibrosis risk. Second, we compared
coplanar and non-coplanar external beam APBI treatment
techniques, using two state-of-the-art techniques, VMAT APBI
and stereotactic CyberKnife APBI (CK APBI).
MATERIALS AND METHODS
Patients and CT-Scans
Anonymized CT data of 20 female early-stage breast cancer
patients treated at Erasmus MC were included. We randomly
selected patients that were previously treated with WBI after
breast conserving surgery at our institution. Ethical approval for
this retrospective study was not required according to Dutch
legislation and the Central Committee on Research Involving
Human Subjects. All patients were eligible for APBI according
to the 2017 ASTRO selection guidelines (9) and institutional
guidelines, meaning they were at least 50 years of age and had
a Tis or T1 tumor of <2.5 cm. At Erasmus MC APBI is not used
if the ratio of the PTV to the ipsilateral breast volume is more
than 30%. A dose of 28.5Gy in five daily fractions is prescribed.
TABLE 1 | Planning constraints.
Structure Clinical constraints
PTV coverage 28.5Gy in at least 95%
Ipsilateral breast V30Gy < 20%, V15Gy < 40%
Contralateral breast Maximum dose to 2 cc of 1 Gy
Ipsilateral lung V9Gy < 15%
Contralateral lung V1.5Gy < 15%
Heart Right-sided lesions: V1.5Gy < 5%
Left-sided lesions: V1.5Gy < 40%
All patients had a free breathing planning CT-scan in supine
position with both arms raised. The tumor bed was delineated as
the volume encompassing the seroma, the post-operative changes
and the surgical clips. It was expanded with a uniform margin
of 10mm to create the CTV, excluding the thoracic wall and the
skin. The skin was defined as the first 5mm within the patient
contour. Accounting for daily image guidance, a CTV to PTV
expansion of 5mm was used.
The delineated organs at risk (OARs) included the ipsilateral
and contralateral lungs and breasts, the non-target breast tissue,
defined as the ipsilateral breast minus PTV, and heart.
Treatment Planning
We created coplanar VMAT and non-coplanar CyberKnife
stereotactic APBI plans using Erasmus-iCycle (24). For both
techniques, the 28.5Gy isodose line had to encompass at least
95% of the PTV volume. The maximum allowed dose over
all voxels was 33Gy. Planning constraints are summarized
in Table 1.
Erasmus-iCycle is an optimizer for multi-criterial beam-
profile optimization and optional beam-angle selection
applicable to coplanar and non-coplanar IMRT, VMAT,
and stereotactic RT. It uses a wish-list, including planning
constraints and prioritized objectives. Details and validation
of the algorithm have been described elsewhere (24, 25). Plans
created by Erasmus-iCycle are Pareto-optimal, which means that
it is not possible to improve one objective without deteriorating
another one. The primary endpoint of this study was the
dose distribution in the intermediate and low dose regions.
As these regions are outside the actual target and include
different densities such as lung, there may be a loss of electronic
equilibrium. A Monte-Carlo based dose engine accurately
accounts for these situations. We used the dose engine called
GPUMCD (26).
The APBI wish-list for this study included constraints on the
maximum dose to the PTV, heart and contralateral breast as well
as constraints on conformality. The first objective was to ensure
a PTV coverage of at least 95% of the volume with a minimum
of 28.5Gy. The second objective was to minimize the dose to
the lungs and the ipsilateral breast. The clinical constraints are
detailed in Table 1 and were derived from constraints used in
clinical trials on external beam APBI, and more specifically
stereotactic APBI using a five fraction regimen (27–29). Left- and
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right-sided cases were optimized using separate wish-lists with
different heart constraints.
Starting from a single personalized plan that equally weighted
lung and ipsilateral breast tissue dose, we varied the priorities
in 10 incremental steps. This resulted in 11 plans per patient
and per technique, ranging from maximally sparing the lung to
maximally sparing the ipsilateral breast tissue. During this phase,
the dose and coverage of the PTV and the doses to the other
OARs were kept constrained to their already obtained values. The
prioritization weights varied from a maximum reduction of dose
to the breast tissue to a maximum reduction of the lung dose, in
nine incremental steps in between. This resulted for each patient
in 11 Pareto-optimal plans per technique, covering the full range
of lung and breast dose sparing possible.
Coplanar VMAT was planned using 27 coplanar beams with
10◦ separation to create an arc of 260 degrees. For left-sided cases,
the arc ranged from 280 to 180◦ and for right-sided cases from 80
to 180◦. The non-coplanar CyberKnife technique used a multi-
leaf collimator and a set of 41 nodes typically used clinically. For
both techniques the energy was 6MV. The planning optimization
for the two techniques used the same wish-list, to ensure that
trade-offs between PTV coverage, conformality, and organ at
FIGURE 1 | Dose distributions for an example case. The dose distributions on the left show coplanar VMAT plans, on the right non-coplanar CyberKnife (CK) plans.
The upper dose distributions are plans with maximum priority to sparing of the breast tissue, and the lower dose distributions are plans with maximum sparing of the
lungs. The middle dose distributions are plans with equal priorities to the sparing of lung and breast tissue.
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risk sparing were identical between the coplanar and non-
coplanar plans.
Analysis
For all plans, we collected an identical set of dose parameters
including PTV coverage and mean doses to the lungs, the entire
ipsilateral breast, the non-target ipsilateral breast tissue, and
the heart.
We calculated the risk of ipsilateral breast fibrosis using
the model of Avanzo et al. with complete repair, since
the fractionation was once daily (30). The parameters
used were BEUD50 = 107.2Gy, volume parameter
FIGURE 2 | Average DVHs for the different treatment plans. Coplanar VMAT plans are shown in (A), non-coplanar CyberKnife (CK) plans are shown in (B). The solid
lines show the results for the plan that fully prioritizes lung sparing. The dashed lines show the result of the treatment plan that fully prioritizes breast sparing.
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TABLE 2 | Dose parameters and toxicity risks.
Coplanar Non-coplanar
Breast sparing Equal priorities Lung sparing Breast sparing Equal priorities Lung sparing
PTV coverage (%) 95.9 (95.6–96.1) 95.9 (95.7–96.0) 96.5 (96.0–96.9) 95.7 (95.4–96.1) 95.5 (95.2–95.9) 96.8 (96.5–97.4)
Lungs mean dose (Gy) 1.9 (1.6–2.2) 1.4 (1.0–1.6) 0.4 (0.3–0.8) 2.2 (2.0–2.5) 1.1 (0.7–1.2) 0.3 (0.2–0.4)
Ipsilateral breast mean dose (Gy) 8.0 (6.8–9.7) 8.4 (7.0–10.1) 11.5 (8.4–12.9) 7.3 (5.4–8.7) 8.2 (6.2–9.4) 12.4 (9.6–13.7)
Non-target breast tissue mean dose (Gy) 4.8 (4.1–5.7) 5.1 (4.4–6.2) 8.3 (6.2–9.4) 3.7 (2.6–4.5) 4.4 (3.5–5.5) 9.8 (7.5–10.5)
Heart mean dose (Gy)
Left-sided cases 2.3 (1.7–3.3) 1.8 (1.2–3.3) 0.6 (0.2–2.6) 2.0 (1.5–3.0) 1.2 (0.5–2.8) 0.3 (0.1–1.3)
Right-sided cases 0.6 (0.6–0.7) 0.6 (0.5–0.6) 0.4 (0.2–0.5) 0.7 (0.6–0.7) 0.5 (0.5–0.7) 0.1 (0.1–0.2)
EAR secondary lung cancer 11.3 (9.7–13.3) 8.8 (6.9–9.9) 3.2 (2.4–5.3) 13.7 (12.7–15.1) 7.2 (5.6–8.4) 2.1 (1.5–2.6)
Breast fibrosis risk (%) 7.7 (6.3–8.6) 7.7 (6.3–8.6) 8.2 (6.6–9.1) 7.6 (6.2–8.6) 7.5 (6.2–8.5) 8.0 (6.5–8.9)
All data is shown as median (interquartile range). EAR Excess Absolute Risk per 10,000 patient years.
FIGURE 3 | Pareto fronts for individual patients of the mean doses to the ipsilateral breast and lungs. Non-coplanar CyberKnife (CK) plans are shown in blue circles,
coplanar VMAT plans are shown in red squares. The thick lines show the average over all patients per technique.
n = 0.06, slope of dose response m = 0.22 and α/β
ratio= 3 Gy.
We calculated the risk of secondary lung cancer for all
scenarios using the model of Schneider et al. (5). This model
calculates the excess absolute risk (EAR) of secondary cancer for
an organ at a specified age a and with a radiation exposure at age
x. It takes into account the effects of dose fractionation, repair and
repopulation and is based on the full dose distribution within an
organ. The parameters used were β = 8.0, γ e= 0.002, γ a= 4.23,
agea = 70 years, agex = 50 years, R = 0.83, α = 0.042 Gy-1, and
α/β= 3 Gy.
We compared coplanar and non-coplanar plans with the
Wilcoxon signed rank test. We compared the left-sided and
right-sided cases with the non-parametric unrelated samples
Mann-Whitney U-test. A p-value of 0.05 or less was considered
significant. All statistical analyses were done in SPSS Statistics
version 25.
RESULTS
Ofthe 20 early stage breast cancer patients included in this study,
11 cases were right-sided and 9 were left-sided and the median
Frontiers in Oncology | www.frontiersin.org 5 August 2020 | Volume 10 | Article 1445
Hoekstra et al. Secondary Lung Cancer After APBI
volume of the delineated tumor bed was 11.0 cc (range 1.6–51.7
cc). Themedian volume of the PTVwas 92.2 cc (range 58.6–246.9
cc). The median ratio PTV/ipsilateral breast volume was 15.1%
(range 7.2–22.3%).
Figure 1 shows an example of the dose distributions of
coplanar and non-coplanar plans with different priorities. When
giving more priority to lung sparing, the low dose isodose lines
shift from a more opposing configuration to a more tangent one.
The average DVHs over 20 patients is shown in Figure 2 for the
coplanar and non-coplanar plans for maximum lung sparing and
maximum breast sparing.
For 2 out of 20 patients, the coplanar treatment plans did not
fulfill the clinical heart constraint. In one left-sided case, the heart
was very close to the PTV. The V1.5Gy was 59% with a mean
heart dose of 4.6Gy. The other case was a very medial right-
sided tumor. The V1.5Gy for this case was 22% and the mean heart
dose 1.6Gy. The PTV coverage and the other OAR constraints
were not violated. Conversely, all non-coplanar plans fulfilled all
the constraints.
The dose parameters, secondary lung cancer risks and fibrosis
risks are summarized in Table 2. The results for all plans can
TABLE 3 | Comparison of coplanar and non-coplanar techniques.
Coplanar Non-coplanar Wilcoxon signed
rank test
PTV coverage (%) 95.9 95.6 p < 0.001
Lungs mean dose (Gy) 1.3 0.9 p < 0.001
Ipsilateral breast mean dose (Gy) 9.0 8.3 p < 0.001
Non-target breast tissue mean
dose (Gy)
5.6 4.7 p < 0.001
Heart mean dose (Gy) 0.65 0.63 p < 0.001
EAR secondary lung cancer 8.3 6.3 p < 0.001
Breast fibrosis risk (%) 8.0 7.7 p < 0.001
Median values over all plans for all cases per technique. EAR Excess Absolute Risk per
10,000 patient years.
be found in the Supplementary Files. The median reduction
in EAR for secondary lung cancer between the plans with
maximum lung sparing and the plans with maximum breast
sparing was 5-fold, ranging from 1.1- to 14.8-folds. Comparing
VMAT with CK ABPI, the median absolute difference was 11.6
cases per 10,000 patient years for the non-coplanar CK technique
and 8.1 cases per 10,000 patient years for the coplanar VMAT
technique. The reduction in mean lung dose when prioritizing
lung sparing among all patients ranged from 0.21 to 2.06Gy for
the coplanar technique and from 0.69 to 3.37Gy for the non-
coplanar technique. The median reduction of the dose to the
ipsilateral breast in the breast sparing plans compared with the
lung sparing plans was 3.5Gy for the coplanar technique (range
0.41–4.73Gy) and 5.1Gy for the non-coplanar technique (range
2.21–6.55Gy). This dose difference resulted in only a very small
increase in fibrosis risk of 0.4 and 0.5%, respectively.
Figure 3 shows the Pareto-fronts of all patients of the trade-
off betweenmean lung dose andmean ipsilateral breast dose. The
non-coplanar plans systematically resulted in lower doses to both
lungs and ipsilateral breast tissue (Table 3, Wilcoxon signed rank
test p < 0.001). The Pareto-fronts did not cross for any patient,
meaning that for a given dose to one organ, the dose to the other
organ was higher in the coplanar treatment plan in all cases.
In Table 4, the dose parameters are reported for the left-sided
and right-sided case separately. Using the unrelated samples
Mann-Whitney U-test, there were no significant differences
between the two groups except for the mean heart dose. The
mean heart dose was higher for the left-sided cases for both
techniques and for both the lung sparing plan and the breast
sparing plan.
Figure 4 details the comparison of the breast sparing plan on
the x-axis and the lung sparing plan on the y-axis per individual
patient. A point below the unity line means that the lung sparing
plan had a lower value than the breast sparing plan. The coplanar
plans are shown as circles and the non-coplanar plans as squares.
Figure 4A shows that the absolute secondary lung cancer risks
were lower for the non-coplanar technique than for the coplanar
technique. The fact that the squares are at a larger distance from
TABLE 4 | Dose parameters and toxicity risks for left-sided and right-sided tumor location.
Coplanar Non-coplanar
Breast sparing Lung sparing Breast sparing Lung sparing
Left-sided Right-sided Left-sided Right-sided Left-sided Right-sided Left-sided Right-sided
PTV coverage (%) 95.9 (95.8–96.5) 95.9 (95.6–96.1) 96.7 (96.3–97.3) 96.1 (95.9–96.9) 95.6 (95.4–96.3) 95.7 (95.4–95.9) 97.2 (96.4–97.6) 96.8 (96.6–96.9)
Lungs mean dose (Gy) 1.8 (1.5–2.1) 1.9 (1.6–2.3) 0.4 (0.3–1.1) 0.5 (0.4–0.8) 2.2 (2.0–2.5) 2.2 (2.0–2.6) 0.3 (0.2–0.4) 0.3 (0.2–0.3)
Ipsilateral breast mean
dose (Gy)
8.3 (6.2–9.9) 7.7 (7.4–9.3) 11.8 (8.3–12.9) 11.2 (9.7–12.9) 7.7 (5.1–9.0) 6.8 (5.5–8.4) 12.4 (9.2–13.9) 12.4 (9.7–13.7)
Non-target breast tissue
mean dose (Gy)
4.1 (3.0–6.3) 4.9 (4.5–5.6) 8.2 (4.8–9.7) 8.3 (7.2–9.4) 3.5 (2.0–4.7) 3.8 (2.9–4.4) 8.9 (6.0–10.6) 9.9 (7.7–10.5)
Heart mean dose (Gy) 2.3 (1.7–3.3) 0.6 (0.6–0.7) 0.6 (0.2–2.6) 0.4 (0.2–0.5) 2.0 (1.5–3.0) 0.7 (0.6–0.7) 0.3 (0.1–1.3) 0.1 (0.1–0.2)
EAR secondary lung
cancer
10.8 (9.5–12.5) 11.8 (9.6–14.3) 2.9 (2.1–6.3) 3.5 (2.7–5.5) 13.8 (12.7–15.0) 13.5 (12.6–16.1) 2.1 (1.4–3.0) 2.1 (1.7–2.2)
Breast fibrosis risk (%) 8.5 (6.0–9.0) 6.9 (6.3–8.5) 8.7 (6.2–9.2) 7.1 (6.8–8.9) 8.4 (5.8–8.8) 6.8 (6.2–8.4) 8.7 (6.1–9.2) 7.1 (6.5–8.8)
All data is shown as median (interquartile range). EAR Excess Absolute Risk per 10,000 patient years.
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FIGURE 4 | Scatterplots of the maximum breast sparing plans vs. the
maximum lung sparing plans. (A) shows the secondary lung cancer risk, (B)
the breast fibrosis risk, and (C) the mean heart dose. Non-coplanar
CyberKnife (CK) plans are shown in blue circles, coplanar VMAT plans are
shown in red squares. Data points below the unity line indicate an advantage
for the dose plan on the vertical axis.
the unity line suggests that the differences between the lung
sparing and breast sparing plans were larger for the non-coplanar
technique. The breast fibrosis risks (Figure 4B) are close to the
unity line for both techniques.
The dose to the heart was also reduced in the lung sparing
plans without any specific constraint to do so. The difference in
mean heart dose for the left-sided cases was 1.7 and 1.2Gy for
the non-coplanar and coplanar techniques, respectively. For the
right-sided cases, the difference in mean heart dose was 0.5 and
0.2Gy, respectively. The comparison is shown in Figure 4C.
DISCUSSION
This study shows that it is possible to dramatically reduce the
mean lung dose and hence the risk of secondary lung cancer for
APBI by giving a higher priority to lung sparing. The median
risk reduction was 5-fold, with a range of 1.1–14.8-folds. This
translates into a median absolute risk reduction of 11.6 cases
per 10,000 patient years for the non-coplanar technique and 8.1
for the coplanar technique, which is highly clinically relevant,
as these patients are expected to survive several decades. The
mortality of lung cancer is about 80% (31). Multiplying the
absolute risk reduction by 0.8 shows that minimizing the lung
dose could theoretically reduce the overall mortality of early-
stage breast cancer patients with 9.3 persons per 10,000 patient
years for the non-coplanar technique and with 6.5 persons per
10,000 patient years for the coplanar technique.
Shifting the dose away from the lungs resulted in a higher dose
to the ipsilateral non-target breast tissue. However, the increase in
mean breast dose of 3.5 and 5.1Gy translated into a small increase
in the risk of breast fibrosis of 0.5 and 0.4%-point for the coplanar
and non-coplanar technique, which is not clinically relevant. The
limited increase in the calculated fibrosis risk could be explained
by the NTCP model used, and notably the n parameter of 0.06
used in the model of Avanzo et al. (30). This value means that the
risk of fibrosis is defined primarily by the high dose volume. The
planning constraints that affect the high dose volume are the PTV
constraints. These constraints were kept constant for the plans
with different priorities in our study. This resulted in plans with
very small differences in the dose to the PTV and consequently
in the risk of fibrosis. The differences between the plans with
the different priorities were in the intermediate and low dose
regions, and these regions have a very limited effect in the
fibrosis model.
The Avanzo model for breast fibrosis is the only published
model addressing APBI. One weakness of this model is the
limited data on which it is based as well as the lack of external
validation. However, other models of fibrosis for WBI also found
that this risk mainly depends on the high dose region (32, 33).
Using theWBI fibrosismodel ofMukesh et al. resulted in absolute
fibrosis risks of about 17%, but the differences between the
breast sparing plans and the lung sparing plans remained very
small (32).
An important finding of this study is that the use of
non-coplanar beams always resulted in a more favorable dose
distribution, as shown in Figure 2. In this study we used
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CyberKnife stereotactic radiotherapy, which provides more
degrees of freedom in treatment planning than coplanar VMAT.
The Pareto fronts of the two techniques did not cross for
any patient, and the non-coplanar technique always had the
lowest doses and lowest risks of secondary lung cancer and
breast fibrosis. The non-coplanar technique also had a wider
front, showing a larger dynamic range for sparing of specific
organs. The difference between the techniques was statistically
significant, as is shown in Table 3. The PTV coverage was slightly
closer to 95% for the non-coplanar technique. The aim of our
automated planning technique was to get a coverage of 95%, but
not higher. This means that a coverage closer to 95% is in fact a
better result than a higher coverage. The non-coplanar technique
has more freedom to get a coverage that is close to the requested
value and to reduce doses to other organs.
Incidentally, we found that optimizing lung sparing also
resulted in lower doses to the heart. The mean heart dose in the
lung sparing plans for the left-sided cases was on average 1.7
and 1.2Gy lower than in the breast sparing plan for the non-
coplanar and coplanar techniques, respectively. This is clinically
significant following the model published by Darby et al. who
reported a linear dose-response relationship between mean heart
dose and cardiovascular events without a threshold. This means
that optimizing lung sparing would also result in a lower risk of
cardiovascular events (34–36).
There are some limitations in the present study. We did
not compare all possible external beam APBI techniques. For
example, 3D-conformal APBI is often used, but we have chosen
to use only the coplanar and non-coplanar techniques with the
highest conformality. 3D-conformal APBI would have resulted in
an artificially increased dose to the ipsilateral non-target breast
tissue. Intuitively there are concerns that the lung dose might
be higher with VMAT compared to 3D-conformal RT. However,
Essers et al. showed that the lung dose would be lower with
VMAT when using partial arcs (37). In our study, the optimizer
was free to select from all available beam angles, and it chose
only partial arcs for the lung sparing plans and not for the
breast sparing plans. This is in agreement with the conclusion of
Essers et al.
We have chosen to use Erasmus-iCycle because it can
generate true bias-free comparisons using exactly the same wish-
list for all plans without any human interference. Treatment
plans created in Erasmus-iCycle are based on fluence map
optimization. They need to be converted into segmented dose
plans before the plan is deliverable to a real patient. With the
right algorithm, the difference between fluence map optimized
plans and segmented plans is small (38). The VMAT and CK
would need to be converted using different treatment planning
software with different dose calculation algorithms. This could
influence the results. The dose parameters for our plans with
equal priorities are comparable to the dose levels reported in
literature (23).
We used the full model of Schneider et al. for the calculation
of the secondary lung cancer risk (5). This model takes into
account cell killing and fractionation effects and uses the full dose
distribution in the organ. It is specifically created for radiotherapy
patients, but it is based on limited epidemiological data. The
BEIR VII model is based on more extensive epidemiological
data, but this model is made for radiation protection purposes
and intended for use in low dose exposures only (4). Using this
model would result in the same conclusion, that prioritizing
lung sparing reduces the secondary cancer risk. For this model,
the reduction for non-coplanar CK is 8.9-fold and for coplanar
VMAT 3.9-fold, compared to 6.5- and 3.5-fold, respectively for
the Schneider model.
In conclusion, the risk of secondary lung cancer of external
beam APBI can be greatly reduced by prioritizing lung sparing
during treatment planning. The associated increase in breast dose
did not lead to a relevant increase in fibrosis risk. Lung sparing
also resulted in a lower mean heart dose. Thus, prioritizing
lung sparing could increase the overall survival of early-stage
breast cancer patients by reducing mortality due to secondary
lung cancer and cardiovascular toxicity. The use of non-coplanar
beams resulted in both a lower secondary lung cancer risk and
a lower fibrosis risk which suggests that it should be favored for
breast APBI.
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